Lauder Q4 and full year
This article was originally published in The Rose Sheet
Executive Summary
The Estee Lauder Companies booked net sales of $7.04 bil. in FY 2007, a 9% increase over 2006, the company announces Aug. 16. Skin-care sales were up 8.3% on a reported basis to $2.6 bil., driven by solid sales in Asia and Europe, launches from Estee Lauder and Clinique brands and increasing sales of La Mer and Resilience Lift Extreme Ultra Firming products by Lauder and the 3-Step Skin Care System by Clinique. Fragrance sales rose 7.9% to $1.32 bil. on strong sales in Europe, the Middle East and Africa and the performance of DKNY Red Delicious and Pure White Linen by Estee Lauder. Lauder sold $2.71 bil. worth of makeup, an increase of 8.3% over the prior-year period; firm cites the success of its makeup artist brands. Hair-care revenue shot up 18.3% to $377 mil., with significant contributions from Aveda and Bumble and Bumble sales. Skin care, makeup and fragrance were adversely affected by department store closings, but this was offset by gains in Internet distribution and growth in company's makeup brands and hair care. For the fourth quarter, Lauder recorded net sales of $1.76 bil, up 7% excluding the impact of foreign currency translation. Sales rose in all regions and product categories, the firm says. Lauder projects that net sales in FY 2008 will increase 7% to 9%....
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.